Advertisement

Topics

Schizophrenia Program Receives Positive Regulatory Feedback

07:55 EDT 23 Aug 2017 | PharmPro

Intra-Cellular Therapies announces positive regulatory update on schizophrenia program. The company plans to prepare an NDA submission by mid-2018 for lumateperone in the treatment of the disorder.
Contributed Author: 
Intra-Cellular Therapies, Inc.

Original Article: Schizophrenia Program Receives Positive Regulatory Feedback

NEXT ARTICLE

More From BioPortfolio on "Schizophrenia Program Receives Positive Regulatory Feedback"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Psychiatry
Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...